Values First Advisors Inc. Has $139,000 Stock Holdings in Geron Co. (NASDAQ:GERN)

Values First Advisors Inc. boosted its position in Geron Co. (NASDAQ:GERN) by 13.6% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 30,674 shares of the biopharmaceutical company’s stock after purchasing an additional 3,668 shares during the period. Values First Advisors Inc.’s holdings in Geron were worth $139,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of GERN. Darwin Global Management Ltd. acquired a new stake in shares of Geron in the second quarter valued at approximately $106,185,000. Tokio Marine Asset Management Co. Ltd. acquired a new stake in Geron during the 1st quarter valued at $333,000. Renaissance Technologies LLC bought a new position in Geron during the second quarter worth $3,315,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Geron by 999.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,064,963 shares of the biopharmaceutical company’s stock valued at $6,815,000 after purchasing an additional 1,877,184 shares during the last quarter. Finally, Algert Global LLC bought a new position in shares of Geron in the second quarter valued at about $539,000. Institutional investors own 73.71% of the company’s stock.

Geron Stock Up 1.5 %

Shares of NASDAQ GERN opened at $4.06 on Friday. The stock’s fifty day moving average is $4.38 and its 200 day moving average is $4.26. The stock has a market capitalization of $2.41 billion, a P/E ratio of -11.60 and a beta of 0.50. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.60 and a current ratio of 3.61. Geron Co. has a 52 week low of $1.64 and a 52 week high of $5.34.

Geron (NASDAQ:GERN) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.10) EPS for the quarter, hitting analysts’ consensus estimates of ($0.10). The company had revenue of $0.88 million during the quarter, compared to analysts’ expectations of $0.34 million. Geron had a negative return on equity of 73.79% and a negative net margin of 15,990.68%. Geron’s revenue was up 2941.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.09) EPS. Sell-side analysts forecast that Geron Co. will post -0.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on GERN. Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 target price on shares of Geron in a report on Friday, August 9th. Scotiabank initiated coverage on Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. StockNews.com raised Geron to a “sell” rating in a report on Monday, August 5th. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price objective on shares of Geron in a report on Thursday, August 8th. Finally, Leerink Partners began coverage on Geron in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $6.94.

Geron Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.